
















doi:10.101Exogenous Addition of Minor H Antigen HA-1+
Dendritic Cells to Skin Tissues Ex Vivo Causes
Infiltration and Activation of HA-1-Specific
Cytotoxic T Cells
Yeung-Hyen Kim,1 Florry A. Vyth-Dreese,2 Ellen Schrama,1 Stan Pavel,3 Ingeborg Bajema,4
Els Goulmy,1 Eric Spierings1,5T cells specific for hematopoietic system restricted minor Histocompatibility (H) antigens target normal and
malignant hematopoietic cells. Thus, cellular immune responses against the latter miHAS eradicate the re-
cipient’s hematopoiesis including residual leukemic cells after HLA-matched minor H antigen-mismatched
stem-cell transplantation (SCT). However, there are controversial reports on the role of HA-1 in the devel-
opment of graft-versus-host-disease (GVHD) as well. Here, we address the behavior of HA-1-specific cyto-
toxic T cells (CTLs) in an ex vivo in situ skin explant model wherein HA-1-expressing dendritic cells (DCs)
were added as antigen-presenting cells (APCs). Infiltration and activation of HA-1 CTLs occurred only in
those cases where both HLA-A2 and HA-1 were expressed, either by the skin or by the DCs, or by the com-
bination of HLA-A21 skin and HA-11DCs. These results point toward the role of recipient’s HA-11DCs in
the chimeric patient suffering from GVHD after HA-1-mismatched SCT. Although in our model the
infiltrated and activated CTLs did not cause skin tissue destruction, our results provide a first step in under-
standing the reported association of HA-1 mismatching with clinical GVHD.
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Hematopoietic stem-cell transplantation (SCT) is an
important treatmentmodality for patients with leukemia
and hematologic disorders. Minor histocompatibility
antigen (miHA) disparities between the HLA-matched
donor and recipient induceminorHantigen-specificdo-
nor T cells causing graft-versus-host reactivity (GVHR)Departmentof ImmunohematologyandBloodTransfusion,
n University Medical Center, Leiden, The Netherlands;
ion of Immunology, The Netherlands Cancer Institute,
rdam, The Netherlands; 3Department of Dermatology;
rtment of Pathology, Leiden University Medical Center,
n, TheNetherlands; and 5Department of Immunology,Uni-
Medical Center Utrecht, Utrecht, The Netherlands.
isclosure: See Acknowledgments on page 76.
denceandreprint requests:EricSpierings,PhD,Department
munology, University Medical Center Utrecht, P.O. Box
, 3508 GA Utrecht, The Netherlands (e-mail: e.spierings@
recht.nl).
ecember 11, 2009; accepted August 5, 2010
blished by Elsevier Inc. on behalf of American Society for
Marrow Transplantation
/$36.00
6/j.bbmt.2010.08.006resulting in graft-versus-host disease (GVHD) and
graft-versus-tumor (GVT) responses [1].
miHAs are polymorphic peptides presented in the
context of HLA class I and II molecules (reviewed in:
[2]). miHAs display either broad or hematopoietic sys-
tem restricted expression patterns [3]. As for HA-1, ex-
tensive cellular functional analyses and mRNA studies
showed its exclusive expression on all cells of the hema-
topoietic system and on solid tumors [4]. Additionally,
in an ex vivo human GVHR skin model, no tissue de-
struction by HA-1-specific CTLs occurred, whereas
CTLs specific for the broadly expressed minor H anti-
genHY causedGVHR reactivity comparable to clinical
skin GVHD grade III-IV [5].
The characteristic of differential tissue and cell ex-
pression of miHAS dissects the involvements of minor
H antigens in GVHD and in graft-versus-leukemia
(GVL). Consequently, the hematopoietic system-
restricted miHAS, for example, HA-1, can be applied
for boosting the GVL effect after HLA-matched
HA-1-mismatched SCT [6]. HA-1-based clinical pro-
tocols, such as cellular adaptive immunotherapy and
vaccinations, are currently being implemented in clin-
ical phase I/II trials [6]. The role of HA-1 in inducing69
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still controversial; some studies report association be-
tween HA-1 mismatching and the development of
GVHD, whereas others do not [7-10]. A plausible
explanation for the association of HA-1 with GVHD
would be the presence of patient’s residual dermal an-
tigen presenting cells (APCs) in the skin after SCT [5].
These APCs cells reside for various times in patient’s
skin [11]. Moreover, depletion of the APCs cells pre-
vents skin GVHD, suggesting a role for these cells in
the induction of GVHD [12].
Both the contradictory results on the involvement of
HA-1 in the development of GVHD, and the current
application of HA-1 for boosting the GVL responses,
demand thorough investigation on its putative role in
the development of GVHD. Here, we show that the
association of HA-1 with the development of clinical
GVHD after HLA-matched, HA-1-mismatched SCT
may be explained by the presence of recipient’s APCs
in the GVHD target organs or by crosspresentation of
hematopoietic cell-derived HA-1 by nonhematopoietic
skin cells.METHODS
Dendritic Cells
Monocyte-derived dendritic cells (DCs) were gener-
ated from healthy individuals by culturing peripheral
blood-derived CD141 monocytes with 250 U/mL IL-4
(Genzyme, Cambridge, MA, USA) and 800 U/mL
granulocyte macrophage-colony stimulating factor
(GM-CSF) (Novartis Pharma BV, Arnhem, The Neth-
erlands) for 6 days as described previously [13]. On day
6, the DCs were maturated by culturing on irradiated
(75 Gy) CD40 ligand-transfected mouse fibroblasts
[14] at a DC to fibroblast ratio of 2.5:1 overnight as
described previously [15,16]. Subsequently, DCs were
harvested and phenotypically analyzed by flow
cytometry for cell-surface expression of CD14, CD1a,
CD86, and HLA-DR. To monitor infiltration, DCs
were labeled with carboxyfluorescein diacetate succini-
midyl ester (CFDA-SE, 0.5 mM; Molecular Probes Eu-
rope BV, Leiden, The Netherlands) for 4 min at 37C
in phosphate-buffered saline (PBS). After washing 3
times with PBS supplemented 1% fetal calf serum
(FCS) (Gibco BRL, Breda, The Netherlands), the cells
were used in the skin explant assays.
Cytotoxic T lymphocytes and Epstein Barr
Virus-Transformed B Lymphoblastoid Cell Lines
HLA-A21 HA-1-specific CD81 CTL clone 1.7
and HLA-A2/HY-specific CTL clone 21-17 were
isolated and expanded from peripheral blood from
patients after HLA-matched minor H antigen mis-
matched SCT, as described before [17]. Epstein Barr
virus transformed B lymphoblastoid cell lines(EBV-BLCL) were generated from peripheral blood
mononuclear cells (PBMCs) of healthy blood donors.
All transformed cell lines were cultured in complete
culture medium consisting of Iscoves modified
Dulbecco medium (IMDM) (Biowhittaker, Verviers,
Belgium) supplemented with 5% FCS, 100 U/mL
penicillin, and 2 mM L-glutamine.
Tetrameric HLA Class I/Minor H Antigen
Peptide Complexes
Allophycocyanin (APC)-conjugated tetrameric
HLA-A*0201 molecules in complex with HA-1 peptide
VLHDDLLEA (HLA-A2/HA-1 tetramer), A2/HY
peptide FIDSYICQV, or Flu peptide GILGFVFTL
(HLA-A2/Flu tetramer) were prepared as described
[18], with minor modifications [19] and stored at
220C in 0.5%bovine serum albumin (BSA)/16%glyc-
erol. Tetrameric HLA class I-minor H antigen peptide
complexes showed specific and sensitive staining of
minor H antigen-specific CTLs both in FACS and
confocal laser scanning microscopy (CLSM) analysis in
vitro (data not shown).
Antibodies
Antibodies used were: FITC-conjugated anti-CD8
(1/20 diluted; Becton and Dickinson, San Jose, CA,
USA), FITC-conjugated anti-CD3 (1/20 diluted;DAKO
A/S, Glostrup, Denmark), anti-CD3 (1/200, DAKO),
mouse anti-CD20 (1/500 diluted; DAKO), biotinylated
goat antimouse (1/200 diluted; DAKO), goat anti-APC
(5 mg/mL) and rabbit anti-PE (5 mg/mL) (both from
Biogenesis, Poole, England, UK), Cy3-conjugated goat
antirabbit (1/400 diluted, Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA, USA), Alexa 633-
conjugated donkey antigoat (5 mg/mL;Molecular Probes
EuropeBV,Leiden,TheNetherlands), anti-GranzymeB
(1/50 diluted, PE-conjugated GB11; Sanquin, Amster-
dam, The Netherlands), rabbit anti-Ki67 (1/200 diluted;
DAKO), and streptavidin-labeled Alexa 568 (12.5 mg/
mL; Molecular Probes Europe BV).
Minor H Antigen Typing
Peripheral blood was obtained from HLA-typed
healthy volunteers after informed consent. PBMCs
were isolated by Ficoll density centrifugation. DNA
was isolated using the local standard procedures used
for HLA typing. miHAs genotyping was performed us-
ing the PCR-SSP technique (Invitrogen Corporation,
Carlsbad,CA,USA).The details of theminorHantigen
typing methodology have been described before [20].
Skin Samples
After informed consent, punch biopsies of 4-mm
diameter were taken from the upper part of gluteal
region of healthy volunteers. The skin was anesthe-
tized with 2% xylocaine with 0.12% adrenaline. The
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human material was collected by protocols approved
by the local ethical committee of the LeidenUniversity
Medical Center (P03-135).
Skin Explant Assay
DC infiltration into skin explant tissues
Punch skin biopsies were dissected into 4 equal
sections under sterile conditions. Skin sections were
placed in 96-well V bottom microtiter culture plates
with dermis orientated upwards and cocultured with
5  105 CFDA-SE-labeled mature DCs or medium
alone overnight. All skin donors were unrelated to
the DC donors and none of the DC-skin combinations
were fullHLAmatched. Assayswere performed in a to-
tal volume of 200 mL IMDM supplemented with 10%
human serum at 37Cand 5%CO2 for 2, 24, 48, and 72
hours (Figure 1A). After serial incubations at various
time points, skin explant tissues were formalin-fixed
and paraffin-embedded. Subsequently skin explant tis-
sues were sectioned and stained with either hematoxi-
lin/eosin (H&E) or multicolor fluorescence. Presence
or absence of DC infiltration was examined by scoring
CFDA-SE labeled DCs per section using CLSM.
Adapted skin infiltration protocol
for optimization of infiltration of DC
and HA-1-specific CTLs
Basically, the skin explant assays were performed as
described above. To optimize mature DC infiltration
without detrimental effects in skin, variable numbers of
mature DCs, ranging from 125  103 to 5  105 per
well, were cocultured for 24 hours. GVHRwas analyzed
at the time points 24, 48, and 96 hours, that is, 0, 24, and
72 hours, respectively, after washing of the cocultures
(Figure 1D). Subsequently, the skin explant tissues
were analyzed byH&E staining to determine semiquan-
titatively the degree of skin infiltration by mature DCs.
Skin tissues of donors with different HLA- and HA-
1-phenotypes (HLA-A21/2 and/orHA-11/2)were incu-
batedwithDCsofdifferentHLA-andHA-1-phenotypes
(HLA-A21/2 and/or HA-11/2) for 24 hours. After re-
moval of noninfiltrated mature DCs and extensive wash-
ing, the skin explant tissues were cocultured with 1 106
HA-1-specific CTLs for 72 hours. Similarly, HLA-A21
female (HY2) skin with HLA-A21 male (HY1) mature
DCs were incubated with HLA-A2/HY-specific T cells
as a positive control. Subsequently, skin explant tissues
were either snap frozen in Tissue-Tek OCT compound
(Sakura, Zoeterwoude, The Netherlands) for immuno-
fluorescence analyses or fixed in formalin, sectioned,
and stained with H&E for histopathologic grading.
Skin GVHD Grading
The histopathologic grading of formalin-fixed and
paraffin-embedded skin explants was assessed andconfirmed independently. Skin GVHR was scored
according to the scoring system of Lerner [21]. The
grading system was as follows: grade 0, normal skin;
grade I, mild vacuolization of epidermal basal cells;
grade II, diffuse vacuolization of basal cells with scat-
tered dyskeratotic bodies; grade III, subepidermal cleft
formation; and grade IV, complete epidermal separa-
tion. Because incubation with autologous PBMC or
medium alone can result in GVHR grades 0, I, and
II [5] (Figure 1C), these scores were considered as
background.
Detection of HA-1 CTL Activation
on Cytocentrifuged Preparations
For detection of infiltrated and activated HA-
1-specific CTLs upon coculture with HA-1-positive
or -negative EBV-BLCL, a triple-staining method was
used combining CD3, CD20, and either Granzyme B
or Ki67. Acetone-fixed cytocentrifuge preparations
were preincubated for 30 minutes in 5% (v/v) normal
goat serum (Sanquin) followed by incubation with
mouse anti-CD20monoclonal antibody (mab), biotiny-
lated goat antimouse, Streptavidin-conjugated Cy5,
normal mouse serum (Sanquin), PE-conjugated mouse
anti-Granzyme B mab, rabbit anti-PE, Cy3-conjugated
goat antirabbit, normal mouse serum, and FITC-
conjugated anti-CD3. For combination with Ki67, in-
cubation in normal goat serum was followed by rabbit
anti-Ki67 antibody, mouse anti-CD20 mab, biotiny-
lated goat antimouse, Cy3-conjugated goat antirabbit
antibody, Streptividin-conjugated Cy5, normal mouse
serum, and FITC-conjugated anti-CD3.
Detection of HA-1-Specific CTLs by Tetrameric
HLA-A2/HA-1 Peptide Complexes byMulticolor
Staining
For multicolor fluorescence staining of cryopre-
served skin tissues, a fluorescence staining protocol
was used as described previously with minor modifica-
tions [22]. In brief, skin explant tissues preincubated
with mature DCs overnight and HA-1-specific CTLs
for 72 hours were labeled with APC-conjugated
HLA-A2/HA-1 tetramer (10 mg/mL) overnight at
4C with gentle shaking. After washing 3 times with
PBS, the skin explant tissues were cryopreserved.
Acetone-fixed cryosections were preincubated for 30
minutes in 5% (v/v) normal mouse serum (Sanquin)
and subsequently incubated for 30 minutes in goat
anti-APC antibody (Biogenesis), Alexa 633-conjugated
donkey antigoat antibody (Molecular Probes Europe
BV, Leiden, The Netherlands), PE-conjugated mouse
anti-Granzyme B antibody (Sanquin), rabbit anti-PE
(Biogenesis), normal goat serum (Sanquin), Cy3-
conjugated goat antirabbit (Jackson ImmunoResearch
Laboratories, Inc.), and FITC-conjugated mouse
anti-CD8 antibody (Becton and Dickinson, San Jose,
Figure 1. Influx of mature DCs causes skin destruction in skin explant tissues. CFDA-SE-labeled mature DCs were incubated with skin explant
tissues as indicated. (A) Schematic time schedule of the DC reconstitution experiment. Mature DCs were added to the skin explant assay at the
start of the experiments and cocultured untill fixation. (B) GVHR scoring of the samples treated as depicted in A. (*P \.05; **P \.001). (C)
H&E staining of the skin explant assays executed as depicted in A. Scale bar represents 10 mm. Black arrows indicate dermal-epidermal cleft forma-
tion. (D) Schematic time schedule of the adapted DC infiltration protocol. Mature DCs and skin samples were cocultured. After 24 hours the sam-
ples were washed and culturing was extended for another 24 hours (with a total assay time of 48 hours) or 72 hours (with a total assay time of 96
hours) in standard culturing medium. (E) GVHR scoring of the samples following the adapted DC infiltration protocol executed as depicted in D at
various time points. (F) Detailed analysis of the GVHR background at various time points using 0.125  106 mDC following the protocol depicted in
D. In all cases, GVHR scores were grade II or lower. (G) Mature DC infiltration after 96 hours with 0.125  106 mDC. The arrows indicate CFDA-
SE-labeled DCs.
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and analyzed by CLSM.
CLSM Analysis and Scoring of HA-1-Specific
CTL Infiltration
CD8-FITC, Granzyme B-PE (Alexa 568 or Cy3)
and HLA-A2/HA-1 tetramer-APC (Alexa 633 or
Cy5) signals were collected separately on a Leica
TCS SP confocal system (Leica Microsystems,
Heidelberg, Germany) equipped with an Argon-
Krypton-Helium/Neon laser. Images were taken
sequentially using a 40 numerical aperture 1.4objective. Color photomicrographs were generated
as electronic overlays. The skin sections were
scanned in X-, Y-, and Z-axis directions to obtain a
3-dimensional confocal image window. Per confocal
image window, quantitative analysis was performed
in the focal plane with maximum infiltration of cells.
Cells that were triple positive for HLA-A2/HA-1
tetramer, CD8, and Granzyme B were counted ac-
cording to the following scoring system: negative 5
0 or 1 triple positive cell; intermediate 5 2 or 3 triple
positive cells; positive 5 more than 4 triple positive
cells.
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Mature But Not Immature DCs Reconstitute Ex
Vivo Skin Explants without Damaging the Skin
Tissues
Because the goal of our study was to investigate the
presence of hematopoietic HA-11 APCs on the subse-
quent development of GVHR upon addition of HA-
1-specific CTLs, we first studied the influence of the
maturation status of DCs and the numbers of added
DCs on the skin explants samples. Hereto, skin biopsies
were coincubated with 0.5  106 CFDA-SE labeled
mature or immature DCs for 2, 24, 48, or 72 hours,
as schematically depicted in Figure 1A. CFDA-SE-
positive cells were observed in the skin biopsies incu-
bated with matured DCs but not in those incubated
with immature DCs (Supplementary Figure S1). Thus,
onlymatureDCs infiltrated the skin samples.Moreover,
these mature DCs displayed phenotypic characteristics
resembling the phenotype of dermal DCs, that is,
a high expression of CD1a, HLA-DR, and CD86,
and absence of CD14. Consequently, all subsequent
experiments were performed with these mature DCs.
To investigate whether reconstitution with mature
DCs alone might cause skin tissue damage in our
model, skin samples were incubated with 0.5  106
mature DCs for 2, 24, 48, and 72 hours. Figure 1A,
B, and C indeed shows that addition of mature DCs
results in GVHR score III after 24 hours. Reduction
to background GVHR was obtained by extensive
washing after DC incubation (Figure 1D) and by
applying lower doses of mature DCs (0.125  106,
0.25  106, and 0.5  106). Using this adapted skin
DC infiltration protocol, all GVHR scores determined
after 24 hours and 96 hours were below background
(Figure 1E). Thus, because DC infiltration could be
established with 0.125  106 DCs (Figure 1F) without
causing significant GVHR (Figure 1E), all subsequent
experiments were performed with the latter number of
DCs.Infiltration and Activation of HA-1-Specific
CTLs Depends on the Presence of Mature DCs
in HLA-A2/HA-11 Skin
To verify the activation potential of CTLs, HA-
1-specific CTLs were coincubated with HA-11 and
HA-1- EBV-BLCLs in vitro, cytocentrifuged, and
stained with the proliferation marker Ki-67 and the
cytotoxicitymarker granzymeB.Only upon recognition
of their cognate antigen, HA-1-specific CTLs acquired
expression of Ki-67 and displayed an excentrically,
polarized cytoplasmic expression pattern of granzyme
B (Figure 2), indicating their activation.
Subsequently, infiltration and activation of HA-
1-specific CTLs were analyzed in the skin samples
reconstituted with various HLA- and HA-1-types ofmature DCs. Hereto, skin samples of donors with
different HLA- and HA-1-types (HLA-A21/2 and/or
HA-11/2) were preincubated with DCs of different
HLA- and HA-1-types (HLA-A21/2 and/or HA-11/2)
for 24 hours (Table 1). After washing, the skin samples
were coincubated with the HLA-A21 HA-1-specific
CTLs for 3 days and scored for CTL infiltration and
activation using CLSM analysis. Skin samples were con-
sidered to be infiltrated by activatedCTLs ifCTLs triple
stained for HA-1 tetramer/CD8/granzyme B. Infiltrated
activated HA-1-specific CTLs were observed in all skin
biopsies pre-incubated with HLA-A21/HA-11 mature
DCs (Figure 3 and Table 1). Moreover, infiltrated acti-
vated HA-1-specific CTLs were also present in the skin
of HLA-A21/HA-11 individuals, independent of the
HLA- and HA-1 phenotype of the mature DCs.
Interestingly, infiltrated activated HA-1-specific CTLs
were also observed in HLA-A21/HA-12 skin in the
presence of HLA-A22/HA-11 mature DCs. Notably,
all infiltrated CTLs were activated. CTLs were neither
detectable inHLA-A22 skin, nor in combinations where
DCs and the skin were both HA-12. Thus, infiltration
and activation of HA-1-specific CTLs depends on the
HLA-A2/HA-1 phenotype, expressed either by the
exogenously added DCs alone or by a combination of
skin and DCs.
HA-1-Specific CTLs Do Not Cause Severe
GVHR in the Ex Vivo Skin Explant Model
Inmost combinations,HA-1-specificCTLs that in-
filtrated the skin did not cause severe GVHR in DC
reconstituted skin samples (Table 2). Only in 2 specific
combinations was GVHR of grade III or IV observed;
that is, HLA-A21/HA-11 mature DCs in HLA-A21/
HA-11 skin (1 of 3 individuals) and HLA-A21/HA-11
mature DCs in HLA-A2-/HA-11 skin (1 of 6 individ-
uals; Table 2). CLSM analysis of these skin sections re-
vealed granzyme B-expressing HA-1-specific CTLs in
the dermis at the dermal/epidermal junction and around
the edges of the GVHR lesions of HLA-A21/HA-12
skin incubated with A2-/HA-11 mDCs. Thus, HA-1-
specific CTLs can infiltrate skin tissue where they get
activated; these T cells, however, appear, in 7 of the 9
combinations, not to be able to induce GVHR in our
ex vivo skin explantmodel. Positive control experiments
using HLA-A21 female (HY2) skin preincubated with
HLA-A21 male (HY1) mature DCs resulted in
GVHR grade III after 3 days incubation with HLA-
A2/HY-specific T cells, indicating that collateral dam-
age can be measured in our adapted skin explant model
(Supplementary Figure S3).DISCUSSION
Several studies reported the influence of the minor
H antigen HA-1 on the development of GVHD after
Table 1. Infiltration of Activated HA-1-Specific CTLs in Skin
Explants Depends on HLA- and HA-1-Phenotype of the Skin
and the DC
mDCs Medium A2+/HA-1+ A2+/HA-12 A22/HA-1+ A22/HA-12
Skin
A2+/HA-1+ 0/5 3/3 5/5 5/5 3/3
A2+/HA-12 0/2 1/1 0/2 2/2 0/1
A22/HA-1+ 0/3 3/3 0/3 0/3 0/3
A22/HA-12 0/2 2/2 0/2 0/2 0/2
HA-1-specific cytotoxic T cells (CTLs) and dendritic cells (DCs) were
induced to infiltrate skin explant tissues according to the adapted skin
infiltration protocol as described in Materials and Methods. Granzyme
B positivity was defined as a polorized intracellular staining pattern. Ac-
tivated infiltrated CTLs were scored as HA-1 tetramer/CD8/granzyme
B triple-positive cells by confocal laser scanning microscopy (CLSM)
analysis. Results are depicted as number of samples with positive score
per total number of samples tested.
Figure 2. Activation of HA-1-specific CTLs depends upon recognition of their cognate antigen. HA-1 specific CTLs were cocultured with
HA-1-positive (A, C) or HA-1-negative (B, D) EBV-BLCL. Activation was monitored by immunofluorescent triple-color staining on cytocentrifuge prep-
arations. EBV-LCL were visualized with anti-CD20 (blue) and T cells with anti-CD3 (green) in combination with either activated cytotoxic cell marker
Granzyme B (red; A and B) or nuclear activation marker Ki67 (red; C and D). Activated and unactivated HA-1-specific CTLs have been marked by red
and white arrows, respectively. Original magnification is 400; scale bar represents 10 mm.
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understood because the minor H antigen HA-1 is he-
matopoietic system-specific and neither functional
studies nor mRNA analyses show expression of HA-1
on nonhematopoietic cells including melanocytes,
keratinocytes, and fibroblasts [23,24]. Additionally,
HA-1-specific CTLs neither infiltrated nor destroyed
skin tissue in an ex vivo in situ skin explant model,
despite the fact that the skin donors were HLA-A21/
HA-11 [5]. Based on these previous experimental
data, it is unlikely that mismatches in hematopoietic
system specific miHAS, like HA-1, are involved in
GVHD. However, the previous studies were either
performed on cultured cell lines or on ex vivo skin tis-
sues devoid of minor H antigen expressing APCs.
Therefore, those studies could not address mecha-
nisms like crosspresentation of APC-derived HA-1
on nonhematopoietic skin cells or collateral damage
of skin tissue as a result of the interaction between
HA-1-specific T cells and residual APCs in the skin.
To address these questions, we adapted the skin ex-
plant assay by reconstituting the skin tissues withprofessional APCs. This step appeared to be essential,
as the number of endogenous dermal DCs decreases
during the skin explant assay (Supplementary
Figure 2). We here show that the association of HA-
1 with the development of clinical GVHD after
Figure 3. Infiltration and activation of HA-1-specific CTLs detected by in situ combined tetramer staining. HA-1 CTLs were cocultured with DC-
preincubated skin explants according to the adapted skin infiltration protocol described in Materials andMethods. Activated HA-1-specific CTLs (yellow
arrows) were identified by triple-color staining for HLA-A2/HA-1 tetramer (blue), CD8 (green), and polarized Granzyme B (red). Scale bar represents
10 mm.
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SCT may be explained by the presence of recipient’s
APCs in the GVHD target organs. Namely, upon
coincubation with HLA-A21/HA-11 DCs, skin-
infiltrated HA-1-specific CTLs express the activated
CTL marker Granzyme B. However, those CTLsTable 2. HA-1-Specific CTLs DoNot Induce Severe GVHR in
the Skin Explant Model
MDCs Medium A2+/HA-1+ A2+/HA-12 A22/HA-1+ A22/HA-12
Skin
A2+/HA-1+ 0/8 1/3 0/8 0/8 0/3
A2+/HA-12 0/4 0/3 0/2 0/2 0/1
A22/HA-1+ 0/5 1/6 0/3 0/3 0/3
A22/HA-12 0/3 0/3 0/2 0/2 0/2
HA-1 cytotoxic T cells (CTLs) and dendritic cells (DCs) were induced to
infiltrate skin explant tissues according to the adapted skin infiltration
protocol as described in Materials and Methods. Results are depicted
as number of samples with positive graft-versus-host reactivity
(GVHR) score (grade III or IV) per total number of samples tested.
Positive control experiments using HLA-A2+ female (HY2) skin with
HLA-A2+ male (HY+) mature DCs results in GVHR grade III after 3
days incubation with HLA-A2/HY-specific T cells, indicating that collat-
eral damage can be measured in our adapted skin explant model.were not able to cause GVHR grade III/IV, whereas
HLA-A2/HY T cells do (Supplementary Figure S3).
This observation is potentially because of lower infil-
trations rates of the HA-1-specifc T cell clone or
a lower lytic capacity. Limitation in the time frame
of the skin explant model hampers extension of the in-
cubation time to overcome such potential problems;
GVHR in control samples raise to grade III/IV after
96 hours.
Residual host APCs in the skin may play an impor-
tant role in the immunopathogenesis of skin GVHD.
Merad et al. [12] demonstrated in mice studies that
depletion of host-derived residual APCs cells, prevents
skin GVHD. The level of donor chimerism increased
with the dose of coadministered allogeneic T cells.
Apparently, these T cells are able to remove recipient
APCs cells efficiently. This allorecognition of residual
host APCs—which could potentially result from
the cognate interaction between HA-11 recipient-
derived APCs in the skin and donor-derived HA-
1-specificT cells—may cause localGVHD.This effect
can result from direct or indirect destructed skin tissue.
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age. Collateral damage has been studied in the context
of hepatitis. Serious hepatitis can result from collateral
damage caused by virus-specific CTLs in influenza
infection [25]. Our data suggest that collateral damage
may not be active in HA-1-mediated GVHD.
Namely, HA-1-specific CTLs recognize the residual
hematopoietic-restricted minor H antigen HA-1
presenting DCs, whereas no infiltration occurred in
HLA-A2-skin or in HA-1-DC/skin combinations.
Surprisingly, HA-1-specific infiltrated and activated
T cells were not causing GVHR in the skin reconsti-
tuted with HLA-A21HA-11DC, which could poten-
tially be because of the phenotype of the HA-1 specific
CTLs. A previous report suggests that perforin-
granzyme B mediated lysis appeared to be restricted
by direct allo-recognition, while FasL-mediated lysis
is responsible for collateral damage to self cells during
an allogeneic response [26]. The HA-1-specific T cells
used in the present study express perforin-granzyme B.
Direct destruction of GVHD target tissues that do
not express the HA-1 antigen requires transfer of HA-
1 antigen from hematopoietic cells to the nonhemato-
poietic cells. Various mechanisms for antigen transfer
have been described, including cellular acquisition of
MHC/antigen complexes via exosome-resembling
microvesicles [27]. These microvesicles are involved
in the functional transfer of MHC/antigen complexes
to follicular DCs and between different DCs [28].
They thereby act as important vehicles for spreading
of antigen-specific signals. Similarly, these vehicles
can transfer membrane-bound MHC/antigen com-
plexes from T cells to APCs [29]. Because we also
observed infiltration and activation of HA-1-specific
T cells in HLA-A22, HA-12 skin reconstituted with
HLA-A21, HA-11 DCs, we cannot fully exclude
transfer of membrane boundMHC/antigen complexes
as a mechanism. It is, however, likely that in the partic-
ular combination of HLA-A21, HA-11DCs in HLA-
A22HA-12 skin, the observed activation is because of
a cognate interaction of the reconstituted DCs with
the HA-1-specific T cells. Moreover, transfer of only
HLA molecules is irrelevant in the HLA-identical
SCT setting, as the transferred HLA molecules of
donor origin are identical to those expressed by the
recipient.
Neijssen et al. [30] demonstrated that exchange of
intracellular peptides can occur via gap junctions.
Transfer through gap junctions applies to peptides
with a relative molecular mass of up to approximately
1800. This intercellular peptide transfer results in
CTL recognition of adjacent, innocent bystander cells.
It is possible that in our system, antigen exchange be-
tween hematopoietic cells and nonhematopoietic cells
may occur; the combination of HLA-A21 HA-12 skin
reconstituted with HLA-A22 HA-11 DCs leads to
activation of HA-1-specific T cells in the skin. Thefact that T cell activation was observed in all DC-
reconstituted HLA-A21HA-11 skin samples, indicates
that also under normal conditions, nonhematopoietic
tissues may acquire antigens from hematopoietic cells
trafficking via the skin. In these combinations, the added
mature DCs facilitate the infiltration of the HA-1-
specific T cells into the skin, where the T cells can sub-
sequently target nonhematopoietic skin cells that may
have acquired the HA-1 antigen from autologous DCs
prior to skin tissue sampling. The role of chemokines
and chemokine receptors in the infiltration process is
currently under investigation.
In summary, we show that reconstitution of skin
samples with mature DCs facilitates infiltration and
activation of HA-1-specific T cells. Although these
CTLs were activated, they were not able to cause
GVHR grade III/IV, possibly as a result of limitations
of the model system. Moreover, our T cell activation
data may imply that autologous residual minor H anti-
gen HA-1-positive dermal DCs could potentially
transfer their antigens to skin cells, leading to cognate
antigen recognition, T cell activation, and destruction
of the skin. These observationsmay help to understand
the earlier reported involvement of HA-1 in the devel-
opment of clinical GVHD.ACKNOWLEDGMENTS
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